TG Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
$TGTX
Biotechnology: Pharmaceutical Preparations
Health Care
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): May 27, 2026
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
(State or Other Jurisdiction
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
of Incorporation)
|
|
|
(Address of Principal Executive Offices)
(212 ) 554-4484
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities filed pursuant to Section 12(b) of the Act:
|
Title of Class
|
Trading Symbol(s)
|
Exchange Name
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 8.01.
|
Other Events
|
On May 27, 2026, TG Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Phase 3 ENHANCE trial, a randomized, double-blind study evaluating a consolidated single infusion regimen for initiation of BRIUMVI® (ublituximab-xiiy) in adults with relapsing forms of multiple sclerosis (RMS). A copy of the press release is being filed herewith as Exhibit 99.1 and incorporated into this Item by reference.
Item 9.01. Financial Statements and Exhibits.
|
Exhibit No.
|
Description
|
|
|
99.1
|
||
|
|
|
|
|
Exhibit 104
|
The cover page from this Current Report on Form 8-K formatted in Inline XBRL.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
TG Therapeutics, Inc.
|
|
|
|
(Registrant)
|
|
|
Date: May 27, 2026
|
By:
|
/s/ Sean A. Power
|
|
|
|
Sean A. Power
|
|
|
|
Chief Financial Officer
|